Compounds > abiraterone
Page last updated: 2024-09-04

abiraterone and dasatinib

abiraterone has been researched along with dasatinib in 5 studies

Compound Research Comparison

Studies
(abiraterone)		Trials
(abiraterone)		Recent Studies (post-2010)
(abiraterone)		Studies
(dasatinib)		Trials
(dasatinib)		Recent Studies (post-2010) (dasatinib)
942978542,7072162,081

Protein Interaction Comparison

ProteinTaxonomyabiraterone (IC50)dasatinib (IC50)
Aurora kinase AHomo sapiens (human)2.633
Mitogen-activated protein kinase 13Homo sapiens (human)0.1
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)0.109
Bile salt export pumpHomo sapiens (human)10
Tyrosine-protein kinase ABL1Homo sapiens (human)0.9374
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)0.1922
Epidermal growth factor receptorHomo sapiens (human)0.7144
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.164
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.71
Tyrosine-protein kinase LckHomo sapiens (human)0.0015
Proto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)0.0004
Tyrosine-protein kinase FynHomo sapiens (human)0.0012
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0078
Tyrosine-protein kinase YesHomo sapiens (human)0.0006
Tyrosine-protein kinase LynHomo sapiens (human)0.0012
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.2665
Tyrosine-protein kinase HCKHomo sapiens (human)0.001
Platelet-derived growth factor receptor betaHomo sapiens (human)0.028
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0276
Breakpoint cluster region proteinHomo sapiens (human)0.4946
Fibroblast growth factor receptor 1Homo sapiens (human)0.88
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.0015
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.0365
Tyrosine-protein kinase BlkMus musculus (house mouse)0.008
Ephrin type-A receptor 2Homo sapiens (human)0.0689
Ephrin type-B receptor 2Homo sapiens (human)0.0044
Vascular endothelial growth factor receptor 2Homo sapiens (human)2.36
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)1.7
Tyrosine-protein kinase CSKHomo sapiens (human)0.0013
Tyrosine-protein kinase TecHomo sapiens (human)0.297
Tyrosine-protein kinase TXKHomo sapiens (human)0.0003
Tyrosine-protein kinase SYKHomo sapiens (human)4.82
Casein kinase I isoform alphaHomo sapiens (human)0.001
LIM domain kinase 1Homo sapiens (human)0.6097
LIM domain kinase 2Homo sapiens (human)0.5186
Mitogen-activated protein kinase 12Homo sapiens (human)0.1
Ephrin type-B receptor 4Homo sapiens (human)0.001
Serine/threonine-protein kinase SIK1Homo sapiens (human)0.001
Myelin transcription factor 1Homo sapiens (human)0.063
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)1.7
Tyrosine-protein kinase BTKHomo sapiens (human)0.0036
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)0.0143
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)0.228
Protein-tyrosine kinase 6Homo sapiens (human)0.0071
Mitogen-activated protein kinase 11Homo sapiens (human)0.1
Mitogen-activated protein kinase 14Homo sapiens (human)0.1
Discoidin domain-containing receptor 2Homo sapiens (human)0.1127
Aurora kinase BHomo sapiens (human)6.485
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)0.104
Serine/threonine-protein kinase SIK2Homo sapiens (human)0.003
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)2
Serine/threonine-protein kinase SIK3Homo sapiens (human)0.005

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ1
Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F1
Dorff, TB; Goldkorn, A; Groshen, S; Gross, ME; Kuhn, P; Pinski, JK; Quinn, DI; Sadeghi, S; Tsao-Wei, D1
Aparicio, A; Araujo, JC; Boukovala, M; Corn, PG; Efstathiou, E; Hoang, A; Kim, J; Logothetis, CJ; Pagliaro, L; Spetsieris, N; Subudhi, SK; Tannir, NM; Troncoso, P; Tsikkinis, A; Tu, SM; Wang, J; Wang, X; Weldon, JA; Wen, S; Zurita, AJ1

Reviews

2 review(s) available for abiraterone and dasatinib

ArticleYear
Novel therapies for metastatic castrate-resistant prostate cancer.
    Journal of the National Cancer Institute, 2011, Nov-16, Volume: 103, Issue:22

    Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays

2011
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Cancer treatment reviews, 2016, Volume: 44

    Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid

2016

Trials

2 trial(s) available for abiraterone and dasatinib

ArticleYear
Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).
    Clinical genitourinary cancer, 2019, Volume: 17, Issue:4

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Treatment Outcome

2019
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
    Clinical genitourinary cancer, 2021, Volume: 19, Issue:1

    Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Random Allocation; Sunitinib; Treatment Outcome; Tumor Microenvironment

2021

Other Studies

1 other study(ies) available for abiraterone and dasatinib

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013